Researchers at the National Cancer Institute in Bethesda, Maryland are seeking 40 patients with the asbestos-related illness mesothelioma, who are not surgery or radiation candidates, to test a new drug known as gefitinib.
Gefitinib is used in the treatment of many types of locally advanced or metastatic lung cancer in patients who previously underwent chemotherapy treatments. Gefitinib prevents cell growth in cancerous cells by targeting proteins located in the cells. Proteins are typically high in cancer cells.
Malignant mesothelioma is found in the mesothelium, the thin layer of tissue that lines the area around the heart, chest cavity and the abdominal cavity, as well as the outer surface of most of the organs. The cancer is often caused by exposure to asbestos.
asbestos is a naturally-occurring mineral with long fibers that possess unique qualities. Throughout the 20th century, asbestos was an ideal choice for use by industries that were manufacturing products that required versatility, heat resistance and durability.
The prognosis associated with mesothelioma is often poor, as a cure does not currently exist and treatment options may be minimal since the cancer is typically not diagnosed until it has progressed within the body. mesothelioma often resembles less-serious conditions, making diagnosis difficult.
The study is in Phase II of a clinical trial that researchers hope will determine the efficacy of gefitinib for mesothelioma patients. Participants will receive daily doses of an oral version of gefitinib and will be monitored by clinicians and researchers for up to four years.
Gefitinib has yet to show conclusive evidence that proves it may improve symptoms or extend life in mesothelioma patients, but doctors are hopeful that this last phase of clinical trials will not only demonstrate sufficient data, but will lead to a full FDA approval.
Additional information about mesothelioma and mesothelioma treatments may be found through the mesothelioma Center.